Generic semaglutide in Canada is no longer just a future-market topic. Health Canada announced its first generic semaglutide authorization on 28 April 2026 and a second on 1 May 2026. Those decisions concern defined finished products. They do not make every lower-priced semaglutide listing an authorized generic.
What the May 2026 announcement actually established
In its 1 May news release, Health Canada described the Apotex submission as a generic version of Ozempic and identified the reviewed indication as management of blood glucose in adults with type 2 diabetes. The release also explains the assessment of pharmaceutical equivalence and differences that could affect safety, efficacy or quality.
This is a dated authorization event, not a complete live inventory of every semaglutide product approved since then. It would be inaccurate to assume that the number of products mentioned in a May announcement remains the current total in November.
How to check a current product
Search the Drug Product Database using the complete name or DIN. Match the company, ingredient, dosage form, route and status, then open the current monograph. Keep the check date. A product that copies an Ozempic reference should not automatically be described using a Wegovy indication.
Scroll horizontally to read all columns.
| Term on a webpage | Evidence to request | Do not assume |
|---|---|---|
| Authorized generic | Matching Canadian product record and monograph | All indications from every semaglutide brand transfer |
| Compounded semaglutide | The regulated compounding context | It is an approved generic |
| Unbranded research vial | Its actual classification and documentation | A lower price establishes equivalence |
| Brand-name product | Exact brand and current presentation | All brand records are interchangeable |
Generic and compounded are different descriptions
A generic medicine undergoes a product-review pathway. Compounding concerns preparation for a specific medical context and is addressed in Health Canada’s manufacturing and compounding policy. One category cannot be substituted for the other because both may use the word semaglutide.
For the same reason, a certificate of analysis is not the missing authorization record. It may report a chemical test, but it does not show that a finished product completed the generic-drug review process. The compounding guide explains the distinction in more detail.
What approval does not tell you about price
The expectation of lower prices is different from a verified quote for a particular prescription and pharmacy. Strength, presentation, dispensing fees and coverage can affect an individual cost. This article does not assign a universal monthly Canadian price or a guaranteed percentage saving.
Approval also does not establish inventory at every pharmacy. Product status and local stock answer different questions. Keep any cost or coverage comparison dated and tied to the exact product.
A record-matching example
Suppose two pages advertise “generic Ozempic.” One gives a product name and DIN that match the database; the other gives only an ingredient name and an analytical percentage. The second listing has not supplied the same kind of evidence. The appropriate next step is to resolve the product identity, not to infer that the two listings are equivalent.
Use the DIN guide for the matching fields and Ozempic versus Wegovy in Canada for the brand distinction. This guide helps interpret records; it does not recommend a product or a treatment switch.
